DONATE

Hybrid IBEC Seminar: Cesar Rodriguez-Emmenegger

Bio-inspired soft matter at the service of interactive biointerfaces and synthetic cells Cesar Rodriguez-Emmenegger, Group Leader, DWI-Leibniz Institute for Interactive Materials Nature achieves unmatched functionality by the self-assembly of (macro)molecular … Read more

Faster Future campaign against Parkinson’s culminates with new scientific breakthroughs

IBEC Faster Future program has made possible, over the last two years, and thanks to donor contributions, the study of antibodies as the basis of a therapeutic product for the treatment of Parkinson’s. The researchers now present the scientific advances and will continue working to try to respond to one of the greatest challenges of modern medicine: neurodegenerative pathologies such as Parkinson’s.

LEITAT and IBEC will promote last generation biotechnologies from Barcelona

A recent alliance between the LEITAT Technological Center and the Institute for Bioengineering of Catalonia (IBEC) will give a new impulse in the development and application of cutting-edge technologies that will combine engineering and biology to find solutions to health problems. Both institutions have established a new agreement to promote innovation in different scientific and technological areas, including 3D bioprinting with bioinks.

IBEC researchers participate in the “European Researchers’ Night”

Last Friday, September 24, the “European Researchers’ Night” took place, an event that is held on a European scale in more than 300 cities in 30 different countries. The objective of this event is to publicize the diversity of science and its impact on the daily lives of citizens in a close and inspiring way. For yet another year, IBEC has not wanted to miss it and has been present at various activities.

Advance in research against childhood cancer in the #WorldResearchCancerDay

IBEC researchers appear in different media for the recent study senior-authored by Joan Montero and first-authored by Albert Manzano, Senior Researcher and PhD student in IBEC’s Nanobioengineering group in which they have used a state-of-the-art analysis technique to evaluate new drug combinations to successfully treat acute lymphoblastic leukemia.